Product Images Alfuzosin Hydrochloride
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 9 images provide visual information about the product associated with Alfuzosin Hydrochloride NDC 47335-956 by Sun Pharmaceutical Industries, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
chemical-structure - chemical structure
figure-1 - figure 1
figure-2 - figure 2
figure-3 - figure 3
The text describes a graph with the mean change in IPSS Total Symptom Score over 28 and 56 days of treatment, comparing a placebo treatment (N=152) with Alfuzosin hydrochloride extended-release tablets (N=137). The graph shows a statistically significant difference (p < 0.01) between the two treatments.*
figure-4 - figure 4
The text provides a graph showing the mean change from baseline in IPSS Total Symptom Score for a trial of a placebo group (N=150) compared to a group taking Aituzosin hydrochloride extended-release tablets (N=151) over 28 and 56 days of treatment. The graph shows a statistically significant difference at p<0.01.*
figure-5 - figure 5
This is a graph showing the mean change from baseline in peak urine flow rate (mL/s) over 56 days of treatment with a placebo and Alfuzosin hydrochloride extended-release tablets in two separate groups of 167 and 170 individuals respectively. The graph indicates a significant improvement in mean urine flow rate with the use of the medication compared to placebo.*
figure-6 - figure 6
The text is a figure titled "Mean Change from Baseline in Peak Urine Flow Rate (mL/s): Trial 2". It appears to be a comparison between a Placebo group (with N=147) and a group treated with Atuzosin hydrochloride extended-release tablets (with N=136). The figure shows the days of treatment and the peak urine flow rate expressed in mL/s, and indicates that there is a statistically significant difference between the two groups, where the Atuzosin group showed a higher peak urine flow rate than the Placebo group.*
figure-7 - figure 7
The text is describing a figure that shows the mean change from baseline in peak urine flow rate in Trial 3. The figure compares the results of placebo (N=150) to Alfuzosin hydrochloride extended-release tablets (N=151) over a treatment period of 84 days. The statistical analysis shows no significant difference between the two groups (NS p > 0.05).*
label - label
Alfuzosin Hydrochloride Extended-Release Tablets are medicine tables containing USP 10 mg of alfuzosin hydrochloride used for medication purposes. The usual dosage information is available in the package insert. It needs to be stored in a tightly closed, light-resistant container protected from light and moisture at a temperature between 20°C and 25°C (68°F to 77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F) as per USP Controlled Room Temperature. Patient Information is available at ps:fwerw.sunpharma.com/usa/products. It should be kept out of children's reach. NDC (National Drug Code) for Alfuzosin Hydrochloride Extended-Release Tablets is 47335-95681, consisting of 90 Tablets. A pharmacist must dispense the tablets with the patient information. The text further contains information on distribution, manufacturing, and a unique identifier code.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.